These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16332312)

  • 1. Endothelins: pathophysiology and treatment implications in chronic heart failure.
    Teerlink JR
    Curr Heart Fail Rep; 2005 Dec; 2(4):191-7. PubMed ID: 16332312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of endothelin in the pathogenesis of heart failure.
    Teerlink JR
    Curr Cardiol Rep; 2002 May; 4(3):206-12. PubMed ID: 11960589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
    Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
    J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan and the endothelin system in congestive heart failure.
    Ellahham SH; Charlon V; Abassi Z; Calis KA; Choucair WK
    Clin Cardiol; 2000 Nov; 23(11):803-7. PubMed ID: 11097125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will endothelin receptor antagonists have a role in heart failure?
    Spieker LE; Lüscher TF
    Med Clin North Am; 2003 Mar; 87(2):459-74. PubMed ID: 12693734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and perspective of endothelin-1 antagonism in acute heart failure.
    Kiowski W; Suetsch G; Oechslin E; Schalcher C; Brunner-Larocca HP; Bertel O
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S53-7. PubMed ID: 11811379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
    Zhang Y; Oliver JR; Horowitz JD
    Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin antagonism with bosentan: current status and future perspectives.
    Ono K; Matsumori A
    Cardiovasc Drug Rev; 2002; 20(1):1-18. PubMed ID: 12070530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin and heart failure.
    Nambi P; Clozel M; Feuerstein G
    Heart Fail Rev; 2001 Dec; 6(4):335-40. PubMed ID: 11447308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan: a dual endothelin receptor antagonist.
    Rubin LJ; Roux S
    Expert Opin Investig Drugs; 2002 Jul; 11(7):991-1002. PubMed ID: 12084009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pharmacology of endothelin and its antagonist bosentan].
    Clozel M; Roux S
    Ann Endocrinol (Paris); 2000 Feb; 61(1):75-9. PubMed ID: 10790596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial dysfunction in the pulmonary vascular bed.
    Chen YF; Oparil S
    Am J Med Sci; 2000 Oct; 320(4):223-32. PubMed ID: 11061346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure.
    Webb DJ
    Circulation; 1995 Dec; 92(12):3372. PubMed ID: 8521551
    [No Abstract]   [Full Text] [Related]  

  • 14. Endothelin and endothelin receptor antagonism in heart failure.
    Sütsch G; Kiowski W
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S69-73. PubMed ID: 10976786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of endothelin-1 in myocardial failure.
    Sam F; Colucci WS
    Proc Assoc Am Physicians; 1999; 111(5):417-22. PubMed ID: 10519162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
    Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
    Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.
    Kiowski W; Sütsch G; Hunziker P; Müller P; Kim J; Oechslin E; Schmitt R; Jones R; Bertel O
    Lancet; 1995 Sep; 346(8977):732-6. PubMed ID: 7658874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of bosentan in patients with chronic heart failure.
    Kiowski W; Sütsch G; Oechslin E; Bertel O
    Heart Fail Rev; 2001 Dec; 6(4):325-34. PubMed ID: 11447307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists.
    Suresh DP; Lamba S; Abraham WT
    J Card Fail; 2000 Dec; 6(4):359-68. PubMed ID: 11145761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.
    Sütsch G; Bertel O; Kiowski W
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):717-25. PubMed ID: 9110115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.